Search clinical trials for: Methylphenidate Hydrochloride Extended Release Capsule

Total 1198 results

TaiRx, Inc.

Completed

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

Advanced Cancer

Taiwan
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Novartis Pharmaceuticals

Completed

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

Attention Deficit/Hyperactivity Disorder

Germany, United States, Belgium, Colombia, Denmark, Sweden
Rhodes Pharmaceuticals, L.P.

Completed

Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD

ADHD | Attention Deficit Hyperactivity Disorder

United States
Rhodes Pharmaceuticals, L.P.

Completed

Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting

ADHD | Attention Deficit Hyperactivity Disorder

United States
McMaster University
Purdue Pharma, Canada

Completed

A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity

Generalized Anxiety Disorder | Attention Deficit Hyperactivity Disorder | Social Anxiety Disorder | Panic Disorder | Agoraphobia

Canada
Purdue Pharma LP

Terminated

Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) (RE-DAX)

Attention-Deficit/Hyperactivity Disorder

United States
Monash Medical Centre
Monash University

Recruiting

FASST - Fetal Alcohol Spectrum Stimulant Trial (FASST)

Fetal Alcohol Spectrum Disorders

Australia
University of Arizona
National Cancer Institute (NCI)

Recruiting

Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

Oral Leukoplakia | Erythroplakia

United States, Canada
National Cancer Institute (NCI)

Recruiting

Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer

Lung Carcinoma

United States, Canada
Johns Hopkins University
Baylor College of Medicine; National Heart, Lung, and Blood Institute (NHLBI); Temple University

Not yet recruiting

Metformin IN Asthma for Overweight and Obese Individuals (MINA)

Asthma | Overweight and Obesity | Asthma Chronic
Massachusetts General Hospital

Completed

Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD

Autism Spectrum Disorder | Attention-deficit/Hyperactivity Disorder

United States
Maastricht University Medical Center
Shire

Completed

Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity (SPD503-315)

Attention Deficit Disorder

Netherlands
Massachusetts General Hospital

Completed

A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.

Alzheimer Dementia

United States
Dr. Reddy's Laboratories Limited

Completed

A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules

Rosacea

Germany
UCB Pharma

Completed

The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting

Attention Deficit Hyperactivity Disorder
Abbott

Recruiting

Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

Functional Dyspepsia

Malaysia, Armenia
Alvogen Korea

Completed

Phase IV Study of Qsymia in Obese Patients

Obesity

Korea, Republic of
Lee's Pharmaceutical Limited
APOGEPHA Arzneimittel GmbH

Completed

Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder

Overactive Bladder

China
McNeil Consumer & Specialty Pharmaceuticals, a...

Completed

A Safety and Effectiveness Study of Methylphenidate HCl Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder

Attention Deficit Disorder With Hyperactivity
McNeil Consumer & Specialty Pharmaceuticals, a...

Completed

A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple Dose Levels in Adults With Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

Attention-Deficit/Hyperactivity Disorder (ADHD)

United States
The University of Texas Health Science Center,...
National Institute of Mental Health (NIMH)

Completed

Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children

Autism | Attention Deficit Disorder With Hyperactivity

United States
Pfizer

Withdrawn

A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD

Attention Deficit Hyperactivity Disorder
Boehringer Ingelheim

Completed

Pharmacokinetics and Bioavailability Study of Lasolvan Hard Capsules and Effervescent Tablets in Healthy Volunteers

Healthy

Russian Federation
Novartis Pharmaceuticals

Completed

A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Metformin and Nightly Fasting in Women With Early Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Breast Ductal Carcinoma In Situ | Invasive Breast Carcinoma

United States, Italy
Mylan Pharmaceuticals Inc

Completed

Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg

Healthy

United States
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
Xinhua Hospital, Shanghai Jiao Tong University...
Beneo GmbH

Recruiting

Prebiotic Fructans Effect on 1-3 Years Constipated Children's Bowel Habits (CONSTICHILD)

Constipation

China
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg

Healthy

United States
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
Beijing Tiantan Hospital
NeuroDawn Pharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke (EMPHASIS)

Ischemic Stroke, Acute

China
Prof. Huss

Terminated

Adherence to Stimulant Treatment in Attention-Deficit Hyperactivity Disorder (ADHD) Patients (ASTA) (ASTA)

ADHD

Germany
Boston Children's Hospital
National Institute of Mental Health (NIMH)

Completed

Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy

Epilepsy | Attention Deficit Disorder With Hyperactivity

United States
Massachusetts General Hospital
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Completed

An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects

Healthy Volunteers

United States
McNeil Consumer & Specialty Pharmaceuticals, a...

Completed

Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder
OPKO Health, Inc.

Completed

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

Covid19 | Coronavirus | SARS-CoV-2 Infection

United States
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
Lei Lei, MD

Recruiting

Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children. (ADHD)

Attention Deficit Disorder With Hyperactivity | Executive Function Disorder

China
Weill Medical College of Cornell University
Agency for Healthcare Research and Quality (AHRQ)

Completed

Trial of an Intervention to Improve Metformin Persistence and Adherence (TreatMet)

Tolerance | Metformin Adverse Reaction

United States
GlaxoSmithKline

Completed

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

Diabetes Mellitus, Type 2

United States
Cingulate Therapeutics

Completed

CTx-1301 Comparative Bioavailability Study

ADHD

United States
Actavis Inc.

Completed

Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fed Conditions

Healthy

United States
Actavis Inc.

Completed

Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted Conditions

Healthy

United States
Murdoch Childrens Research Institute

Recruiting

Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC) (MARVEL-PIC)

Neoplasms | Bone Marrow Transplantation

Australia
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

China
Shire

Completed

Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

Attention-Deficit/Hyperactivity Disorder

United States, Canada
Ultragenyx Pharmaceutical Inc

Terminated

A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment

Hereditary Inclusion Body Myopathy | GNE Myopathy | Inclusion Body Myopathy 2 | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

Canada, United States, Bulgaria

3

Subscribe